Trials / Recruiting
RecruitingNCT06664125
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Jemincare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
Detailed description
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JMKX003002 will be administered orally | tablets for oral administration. |
| DRUG | Sevelamer carbonate | tablets for oral administration. |
Timeline
- Start date
- 2024-12-30
- Primary completion
- 2025-06-30
- Completion
- 2025-09-30
- First posted
- 2024-10-29
- Last updated
- 2025-02-03
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06664125. Inclusion in this directory is not an endorsement.